CHRNChronoScale Corporation

$21.12

Price

$21.12+572%1Y
1M-6.0%1Y+572%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Not rated
Not enough fundamentals to score this one.
What they do

Founded in 2005, we are a Nevada corporation that designs, develops, and markets exoskeleton products that augment human strength, endurance and mobility. The primary end market for our exoskeleton technology is healthcare, where our technology primarily serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The majority of our sales are generated from our Enterprise Health products, which includes the sales of products and services related to neurorehabilitation in clinical settings.

In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR

P/E (TTM)-
Market Cap$3.34B
1Y Return+572%
5Y Return-72%

Business segments

Q1 2026 · $2.2M

The company’s own SEC segment disclosure.

  • US$1.5M70%
  • Emea Other$314.0K14%
  • FR$207.0K9%
  • APAC Other$40.0K2%
  • Asia Pacific$40.0K2%
  • IT$26.0K1%
  • Other (1)$21.0K1%

ChronoScale Corporation (CHRN) reported revenue of $2.1M in Q1 2026 (quarter ended March 31, 2026), down 37% from the same quarter a year earlier. That came with a gross margin of 50% and net loss of $6.9M. For the full year FY2025, revenue was $13M (−29% year on year) and net income −$12M. Its largest region in 2026-Q1 was US at $1.5M, 70% of the disclosed total, just ahead of Emea Other at 14%.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.